SBIR/STTR Research Award
Dual Targeted Nanoparticle therapy for Glioblastoma Multiforme
Award amount
$224,980Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- AVRYGEN CORPORATION
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- EDYLS6D8L1B7
- Solicitation number
- PAR10-286
- Topic code
- NCI
Research abstract
DESCRIPTION (provided by applicant): Glioblastoma Multiforme is a lethal cancer with devastating prognosis. Glioblastoma affects 5-8 persons per 100,000 population. Even using the most aggressive therapeutic approaches, which include, surgical resection oftumor mass, radiation therapy and chemo intervention, median survival term is less than 15-months. The high recurrence of this cancer is due to remnant reservoir of stem cells (Glioma Stem Cells: GSC) that renew the tumor after resection. Therefore, thereis urgent unmet need to develop novel targeted therapeutics for Glioblastoma that target critical molecular mediators in its reservoir of stem like cells. Results of our preliminary studies drive this proposal. In preliminar studies, we have formulated novel stabilized and targeted nanoparticles for delivery of dual disease specific siRNAs to Glioblastoma stem like cells. Our nanoparticles carry specific targeting moieties that can readily cross the blood brain barrier and home-in to Glioblastoma cell
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Novel physiological depot formulations for long-term butyrylcholinesterase delivery
- Therapy for Secondary Lymphedema
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
3 SBIR/STTR records share this UEI (2012–2014). Reported award amounts total $424,979. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Defense, Department of Health and Human Services